ICU, General Hospital of Thessaloniki "Hippokration", 49th Kostantinoupoleos Street, 57642 Thessaloniki, Greece.
Pulmonary Clinic of Aristotle University of Thessaloniki, General Hospital of Thessaloniki "Georgios Papanikolaou", Leoforos Papanikolaou, Exohi, 57010 Thessaloniki, Greece.
Adv Respir Med. 2023 Jul 4;91(4):288-300. doi: 10.3390/arm91040023.
Long-acting muscarinic antagonists (LAMAs) are a class of inhalers that has recently been included as add-on therapy in the GINA guidelines, either in a single inhaler device with inhaled corticosteroids plus long-acting β2-agonists (ICS + LABA) (closed triple inhaler therapy) or in a separate one (open triple inhaler therapy). This review summarizes the existing evidence on the addition of LAMAs in patients with persistently uncontrolled asthma despite ICS + LABA treatment based on clinical efficacy in the reduction of asthma symptoms and exacerbations, the improvement in lung function, and its safety profile.
长效毒蕈碱拮抗剂（LAMA）是一类吸入剂，最近已被纳入 GINA 指南的附加治疗药物，无论是与吸入皮质类固醇和长效β2-激动剂（ICS + LABA）联合使用的单一吸入装置（密闭三联吸入疗法），还是单独使用（开放三联吸入疗法）。这篇综述总结了基于 LAMA 对接受 ICS + LABA 治疗后仍未得到控制的哮喘患者的临床疗效（降低哮喘症状和恶化，改善肺功能）和安全性概况方面的现有证据，评估了 LAMA 在此类患者中的应用。
